---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-332236"
form_type: "8-K"
ticker: null
cik: "0001808158"
company_name: "Repare Therapeutics Inc."
filed_at: "2025-12-29T23:59:59+00:00"
generated_at: "2026-05-16T12:07:35.240573+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Repare sells Polθ inhibitor RP-3467 to Gilead for up to $30M; Xeno deal per-share value rises to ~$2.20

## Summary
- Gilead will pay up to $30M ($25M upfront + $5M transfer completion) for Repare's RP-3467 Polθ ATPase inhibitor program.
- Repare retains other pipeline programs including RP-1664 and lunresertib/camonsertib.
- Estimated per-share cash payment in pending Xeno acquisition increased to ~$2.20, up from prior estimate due to Gilead upfront cash.
- Asset purchase closed Dec 23, 2025; consent obtained from NYU for assignment of related license agreement.
- CEO Steve Forte noted this is Repare's third and most significant portfolio transaction in 2025.

## SEC filing metadata
- accession: 0001193125-25-332236
- form_type: 8-K
- cik: 0001808158
- company_name: Repare Therapeutics Inc.
- filed_at: 2025-12-29T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808158/000119312525332236/0001193125-25-332236-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808158/000119312525332236/d32279d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-332236
- JSON: https://secwatch.observer/filing/0001193125-25-332236.json
- Plain text: https://secwatch.observer/filing/0001193125-25-332236.txt

## Source-grounded claims
- claim_id: 38e4fd74f7206e361d22113050d1bf098c6d15c9
  claim: Repare Therapeutics Inc. completed a disposition involving Gilead Sciences, Inc. for up to $30,000,000 in cash (closed 2025-12-23).
  evidence_excerpt: contracts, cash, accounts receivable, real property or equipment. Pursuant to the Asset Purchase Agreement, Gilead will pay the Company an aggregate purchase price of up to $30,000,000 in cash, consisting of (i) a $22,000,000 payment due to the Company no later than December 31, 2025, (ii) a holdback amount of up to $3,000,000 that may become payable after one
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808158/000119312525332236/0001193125-25-332236-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.